Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Working Capital Changes (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Other Working Capital Changes data on record, last reported at $12.8 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 162.16% year-over-year to $12.8 million; the TTM value through Dec 2025 reached $8.1 million, up 125.91%, while the annual FY2025 figure was $8.1 million, 125.91% up from the prior year.
  • Other Working Capital Changes reached $12.8 million in Q4 2025 per APLS's latest filing, up from -$12.8 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $20.2 million in Q4 2021 and bottomed at -$38.4 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is -$2.7 million, with a median of -$2.8 million recorded in 2022.
  • Peak YoY movement for Other Working Capital Changes: soared 767.21% in 2021, then crashed 10097.2% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at $20.2 million in 2021, then plummeted by 290.58% to -$38.4 million in 2022, then soared by 83.37% to -$6.4 million in 2023, then plummeted by 221.68% to -$20.6 million in 2024, then soared by 162.16% to $12.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $12.8 million in Q4 2025, -$12.8 million in Q3 2025, and -$10.6 million in Q2 2025.